Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4-ALK-rearranged non-small-cell lung cancer harbored coexisting EGFR mutation

作者：Miyanaga Akihiko; Shimizu Kumi; Noro Rintaro; Seike Masahiro; Kitamura Kazuhiro; Kosaihira Seiji; Minegishi Yuji; Shukuya Takehito; Yoshimura Akinobu; Kawamoto Masashi; Tsuchiya Shinichi; Hagiwara Koichi; Soda Manabu; Takeuchi Kengo; Yamamoto Nobuyuki; Mano Hiroyuki; Ishikawa Yuichi; Gemma Akihiko^*

来源：BMC Cancer, 2013, 13(1): 262.

DOI：10.1186/1471-2407-13-262

• EML4-ALK
• EGFR mutation
• Lung cancer

Background: The EML4-ALK (echinoderm microtubule-associated protein-like 4 gene and the anaplastic lymphoma kinase gene) fusion oncogene represents a novel molecular target in a small subset of non-small-cell lung cancers (NSCLCs). The EML4-ALK fusion gene occurs generally in NSCLC without mutations in epidermal growth factor receptor (EGFR) and KRAS. %26lt;br%26gt;Case presentation: We report that a case of EML4-ALK-positive NSCLC with EGFR mutation had a response of stable disease to both an EGFR tyrosine kinase inhibitor (EGFR-TKI) and ALK inhibitor. %26lt;br%26gt;Conclusions: We described the first clinical report of a patient with EML4-ALK-positive NSCLC with EGFR mutation that had a response of stable disease to both single-agent EGFR-TKI and ALK inhibitor. EML4-ALK translocation may be associated with resistance to EGFR-TKI, and EGFR signaling may contribute to resistance to ALK inhibitor in EML4-ALK-positive NSCLC.

• 出版日期2013-5-29